Immuneering Corp Ownership
| IMRX Stock | USD 2.08 0.02 0.95% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Immuneering |
Immuneering Stock Ownership Analysis
About 29.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.13. Some equities with similar Price to Book (P/B) outperform the market in the long run. Immuneering Corp recorded a loss per share of 1.97. The entity had not issued any dividends in recent years. Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited. Immuneering Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 74 people. To learn more about Immuneering Corp call the company at 617 500 8080 or check out https://immuneering.com.Besides selling stocks to institutional investors, Immuneering Corp also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Immuneering Corp's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Immuneering Corp's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Immuneering Corp Quarterly Liabilities And Stockholders Equity |
|
Immuneering Corp Insider Trades History
About 29.0% of Immuneering Corp are currently held by insiders. Unlike Immuneering Corp's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Immuneering Corp's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Immuneering Corp's insider trades
Immuneering Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immuneering Corp is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immuneering Corp backward and forwards among themselves. Immuneering Corp's institutional investor refers to the entity that pools money to purchase Immuneering Corp's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 92.1 K | Susquehanna International Group, Llp | 2024-06-30 | 88.8 K | Manufacturers Life Insurance Co | 2024-09-30 | 82.6 K | Exchange Traded Concepts, Llc | 2024-06-30 | 74.9 K | Jane Street Group Llc | 2024-06-30 | 74.8 K | State Street Corp | 2024-06-30 | 69.2 K | Tidemark Llc | 2024-09-30 | 51.9 K | Hightower Advisors, Llc | 2024-06-30 | 44 K | Ci Private Wealth Llc | 2024-06-30 | 43.4 K | Vanguard Group Inc | 2024-09-30 | 1.1 M | Millennium Management Llc | 2024-06-30 | 953.2 K |
Immuneering Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immuneering Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immuneering Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immuneering Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immuneering Corp Outstanding Bonds
Immuneering Corp issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immuneering Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immuneering bonds can be classified according to their maturity, which is the date when Immuneering Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Immuneering Corp Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 2nd of October 2024 An amendment to a previously filed Form 8-K | ViewVerify |
F4 | 17th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.